One year after the approval of Journavx (suzetrigine), a first-in-class non-opioid therapy for acute pain, the question ...
LAWRENCEVILLE, N.J.--(BUSINESS WIRE)--Asana BioSciences announced today positive topline results from a Phase 1b study evaluating the treatment of pruritus associated with atopic dermatitis ...
PHILADELPHIA -- An oral, non-addictive sodium channel blocker safely relieved moderate-to-severe acute pain following surgery, according to phase III data that could support regulatory approval.
Site 1 sodium channel blockers such as tetrodotoxin and saxitoxin are small-molecule drugs with powerful local anesthetic properties. They provide pain relief without toxic effects on local nerves and ...
Blockade of voltage-gated sodium channels (NaChs) in pancreatic α cells has anti-diabetic effects, according to research published online May 8 in Diabetes. Arvinder K. Dhalla, Ph.D., of Gilead ...
South Korea’s SK Biopharmaceuticals Co. Ltd. and Shanghai-based Ignis Therapeutic Co. Ltd. signed a ₩804 billion (US$58 million) licensing deal on April 18, granting the latter global rights to a ...
Nocions™ are small molecule charged sodium channel blockers designed to selectively silence activated pain-sensing neurons while sparing normal sensation and motor function Approach enables broad ...
Nat Clin Pract Neurol. 2008;4(3):159-169. Drug Primary clinical use Protective effect during administration in animal models? Effects of withdrawal in EAE Clinical study Phenytoin Treatment of ...
ATS 2009, SAN DIEGO—Cystic fibrosis patients may benefit from a new therapy that increases airway hydration, preventing the buildup of mucous, which is a key factor in the disease, according to ...
Several studies examining the use of sodium-channel blockers in patients with multiple sclerosis are currently underway. Questions about the long-term effects of these agents in neuroinflammatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results